This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The two-stage intervention was introduced alongside the opportunistic screening that usually occurred. Stage one was a mass media campaign inviting the target population, who were considered to be at high risk, for testing for hepatitis B and C. Stage two was ongoing surveillance of high-risk individuals for hepatocellular carcinoma. This was compared with opportunistic screening alone, with less frequency and fewer tests than the intervention.
Location/setting
Taiwan/hospital.
Methods

Analytical approach:
A decision tree, with a one-year time horizon, and a Markov model, with a 60-year time horizon, were developed to assess the costs and outcomes for each strategy for a hypothetical cohort of 100,000 individuals. The disease states included chronic hepatitis, cirrhosis, hepatocellular carcinoma, and death. The authors reported that a government perspective was adopted.
Effectiveness data:
The effectiveness data were from various sources. A screening database of the research foundation that initiated the intervention provided the data for the screening rates and positive test rates with the intervention. A review of medical records and a questionnaire survey of one regional hospital in central Taiwan, selected from the 15 hospitals that participated in the intervention, were used for the screening rates in usual practice. Published studies were used for the annual incidence of hepatocellular carcinoma and its associated mortality. The main outcome measures were the number of hepatocellular carcinoma cases detected and the number of hepatocellular carcinoma deaths averted.
Monetary benefit and utility valuations:
The utility weights were from a published study of the burden of disease and injury in Australia. This study used Dutch weights to measure the severity of a wide range of health conditions.
Results
The total cost was TWD 914.73 million with the two-stage screening intervention, compared with TWD 885.04 million with opportunistic screening; an additional cost of TWD 29.70 million. The mean life-years were 343,604.20 with twostage screening and 343,544.57 with opportunistic screening; a gain of 59.63 life-years. The QALYs were 266,928.36 with two-stage screening and 266,854.51 with opportunistic screening; a gain of 73.85 QALYs.
The incremental cost effectiveness ratio (ICER) of the two-stage screening intervention was TWD 498,000 per life-year saved or TWD 402,000 per QALY gained.
The results were most sensitive to the reduction in mortality due to hepatocellular carcinoma with two-stage screening and the hepatocellular carcinoma incidence. The scenario analysis showed that altering the screening programme to focus on the regular monitoring of high-risk individuals could achieve a more favourable ICER. Assuming stage two hepatocellular carcinoma screening identified 100% of cases and opportunistic screening remained at 28.6% (base case), the ICER was reduced to TWD 443,000 per life-year saved.
The cost-effectiveness acceptability curve suggested that 95% of the simulated ICERs were below TWD 1,070,000 per life-year saved.
